Treatment with Quinoline-3-carboxamide does not successfully prevent immune-mediated glomerulonephritis in mice
Introduction: Quinoline-3-carboximide compounds, such as paquinimod, which targets the protein S100A9, have demonstrated efficacy in treating autoimmune diseases. S100A9, in association with S100A8, forms the heterodimer S100A8/S100A9, known as calprotectin; that has been shown to be upregulated in...
Main Authors: | Juliana Draibe, Ruth J. Pepper, Alan D. Salama |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-11-01
|
Series: | Nefrología (English Edition) |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2013251416300736 |
Similar Items
-
Treatment with Quinoline-3-carboxamide does not successfully prevent immune-mediated glomerulonephritis in mice
by: Juliana Draibe, et al.
Published: (2016-11-01) -
Fibrillary glomerulonephritis presenting as crescentic glomerulonephritis
by: H H Shah, et al.
Published: (2017-01-01) -
An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod
by: Roger Hesselstrand, et al.
Published: (2021-07-01) -
NEW ASPECTS OF FIBRILLARY AND IMMUNOTACTOID GLOMERULONEPHRITIS
by: Maurizio Salvadori, et al.
Published: (2019-07-01) -
Inhibition of DAMP signaling as an effective adjunctive treatment strategy in pneumococcal meningitis
by: Ilias Masouris, et al.
Published: (2017-11-01)